ResMed (ASX:RMD) share price tumbles on broker downgrade

This leading broker believes the ResMed share price has peaked…

| More on:
concerned and worried man looking at computer and monitoring falling share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price is out of form on Tuesday.

In afternoon trade, the sleep treatment focused medical device company's shares are down 2.5% to $31.82.

Despite this decline, the ResMed share price is still up over 17% since the start of the month.

Why is the ResMed share price dropping?

Today's decline appears to have been driven by a combination of broad market weakness and a broker note out of Citi.

In respect to the latter, this morning analysts at Citi downgraded the company's shares to a neutral rating with an improved price target of $32.50.

This was broadly in line with the ResMed share price prior to today's decline.

Why did Citi downgrade its shares?

According to the note, the broker made the move on valuation grounds after a strong gain by the ResMed share price this month.

It notes that this has been driven by news that rival Philips has recalled its DreamStation CPAP devices. And while the broker has upgraded its earnings estimates to reflect its belief that this development could be a short term boost to ResMed's sales, it feels this is now reflected in its shares.

Citi commented: "The recall of Philips' DreamStation CPAP devices creates an opportunity for RMD to fill the void in the short term and potentially make long-term market share gains. Philips is unlikely to be able to supply new patients until Jan 2022 as it ramps up production of its DreamStation 2 – new patients account for ~80% of Philips' CPAP devices sales."

"We upgrade FY22-23e EPS by 5%/10%, increase our TP to $32.50 (from $28.50) but downgrade to Neutral as the share price now reflects our base-case scenario. We assume RMD can increase its CPAP devices and masks manufacturing capacity by 20% and that Philips won't re-enter the new patient market for 12 months – these two variables are the main unknowns. RMD has not made any comments on the situation and will report FY21 in August," it concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Person handing out $50 notes, symbolising ex-dividend date.
Broker Notes

Where to invest $20,000 into ASX 200 shares

Brokers think these shares could be top picks for Aussie investors.

Read more »

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why Macquarie expects this ASX 200 dividend stock to keep outperforming

Macquarie has tipped this ASX 200 dividend stock to outperform. Let’s find out why.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »